Skip to main content

Aldeyra Therapeutics, Inc.

ALDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001341235

No open-market purchases or sales by Aldeyra Therapeutics, Inc. insiders were filed in the last 90 days; 107 institutions reported holding it in 13F filings for Q2 2026, worth $77.7M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding Aldeyra Therapeutics, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of ALDX: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders105101−4
Shares35.1M35.4M+287.7K (+0.8%)
Value$123.3M$115.8M−$7.48M (−6.1%)

New holders (14)

Institutions that held Aldeyra Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to ALDX in Q1 2024
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc178,919$585.1K0.00%
Sherbrooke Park Advisers LLC107,748$352.3K0.07%
AQR Capital Management LLC105,054$343.5K0.00%
Denali Advisors LLC47,300$154.7K0.05%
Cetera Investment Advisers17,977$58.8K0.00%
Algert Global LLC15,670$51.2K0.00%
Mackenzie Financial Corp15,517$50.7K0.00%
Kingswood Wealth Advisors, LLC15,000$49.0K0.01%
Laidlaw Wealth Management LLC12,725$41.6K0.02%
Creative Planning10,686$34.9K0.00%
King Wealth10,000$33.0K0.01%
National Bank of Canada5,500$20.7K0.00%
Catalyst Funds Management Pty Ltd4,760$15.6K0.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC9$290.00%

Sold out (18)

Institutions that held Aldeyra Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.